Ohio Board Of Pharmacy Publishes Updated MMJ Patient & Caregiver Numbers For February 2020

OHIO: The State of Ohio Board of Pharmacy today published updated patient & caregiver numbers for February 2020. These numbers include:

  • 102,200 Recommendations
  • 88,306 Registered patients
    • 6,545 Patients with Veteran Status
    • 6,018 Patients with Indigent Status
    • 506 Patients with a Terminal Diagnosis
  • 64,932 Unique patients who purchased medical marijuana (as reported to OARRS by licensed dispensaries)
  • 9,793 Registered Caregivers

For the full list of program numbers, please visit the Program Update page.

Ohio Board Of Pharmacy Publishes Updated Patient & Caregiver Numbers For January 2020

State_of_Ohio_Board_of_pharmacy_logo2C

OHIO: The State of Ohio Board of Pharmacy today published updated patient & caregiver numbers for January 2020.

These numbers include:

  • 94,771 Recommendations
  • 84,023 Registered patients
    • 6,163 Patients with Veteran Status
    • 5,382 Patients with Indigent Status
    • 473 Patients with a Terminal Diagnosis
  • 60,260 Unique patients who purchased medical marijuana (as reported to OARRS by licensed dispensaries)
  • 9,153 Registered Caregivers

For the full list of program numbers, please visit the Program Update page.

Ohio Board Of Pharmacy Awards Third Dispensary Certificate Of Operation In Cincinnati

State_of_Ohio_Board_of_pharmacy_logo2COHIO:  The State of Ohio Board of Pharmacy today awarded a Dispensary Certificate of Operation to Have a Heart Cincy, located at 8420 Vine St., Cincinnati.

The Board has now issued 47 Dispensary Certificates of Operation.

The interactive map of Dispensaries with Certificates of Operation will be updated within two business days.

Ohio Medical Marijuana Control Program Mandatory Product Recall Update

Ohio Medical Marijuana Control ProgramOHIO: Ohio Medical Marijuana Control Program Mandatory Product Recall Update 11/17

TOPIC: Mandatory Product Recall

 

ISSUE: The Ohio Medical Marijuana Control Program (MMCP) is issuing a patient communication to alert patients about a mandatory product recall. This recall is being initiated by the MMCP due to product development using a non-compliant process.

 

AFFECTED PRODUCTS:

 

Product Names:

Pineapple Express
Blue Boi Z7
Afghani #1

 

Purchase Dates: Any purchase date

 

Processor Name: One Orijin

 

Product ID:
M00000038808: Sol Vap 62.3 – 12.6 – 5
M00000039812: Sol Vap 59.8 – 0.025 – 5
M00000036317: Sol Vap 45.85 – 47.44 – 10
M00000036932: Sol Vap 48.79 – 50.59 – 10
M00000037232: Sol Vap 68.8 – 0.18 – 5
M00000038319: Sol Vap 40.7 – 46.8 – 10

 

No reports of adverse reactions for this product have been reported to the MMCP at this time.

 

Patients who have purchased the recalled product should stop using it. All unused product should be returned to the dispensary where purchased. Returned products will not count toward a patient’s 90-day possession limit. For more information on returns, please contact the dispensary where the product was purchased.

 

Anyone who thinks that they may be experiencing serious or life-threatening issues should seek immediate medical attention. Patients are reminded that any adverse reactions should be reported to the MMCP toll-free helpline (1-833-464-6627).

LeafLine Labs Begins Offering Care To Minnesota Patients Suffering From Intractable Pain

MINNESOTA: As of August 1st, LeafLine Labs, the physician-founded and patient-focused organization formed to cultivate, process and distribute medical cannabis in Minnesota, will be able to dispense medical cannabis to patients suffering from intractable pain.

Intractable pain was added to the list of qualifying conditions for medical cannabis earlier this year by the Minnesota Department of Health. July 1 was the first day health care practitioners were able to certify patients with chronic pain in the state’s medical cannabis program and August 1 is the first day this medicine is available for patients at distribution locations—including four LeafLine Care Centers in St. PaulEagan,Hibbing, and St. Cloud.

“As a caregiving organization dedicated to putting patients first, we welcome this opportunity to improve the quality of life of Minnesotans who bear the burden of chronic pain,” said LeafLine Labs co-founder and CEO Dr. Andrew Bachman. “For too long, dangerous prescription opioids have been used to treat intractable pain when the evidence suggests we should not. Now we can offer a safer alternative—a natural botanically derived medication that treats many causes of chronic pain without the same risk of deadly overdose.”

According to data from the Minnesota Department of Health, the state is experiencing a long-term trend of rising deaths due to drug overdoses, with more than half of drug-related deaths tied to prescription medications. The leading drugs responsible for overdose deaths in 2015 were opioid pain relievers. States with medical cannabis access, according to a 2014 study inJAMA Internal Medicine, have 25 percent fewer deaths from opioid overdose than states without legal medical cannabis.

A recently-published study in Health Affairs showed that patients do indeed turn away from prescription drugs when their state allows medical cannabis as an alternative. In states with legalized medical cannabis, researchers looking at data from Medicare found a decrease in prescriptions for a variety of drugs, for conditions including anxiety, depression, nausea, pain, psychosis, seizures, sleep disorders and spasticity. The drop in prescriptions wasn’t across-the-board: it only appeared for drugs where medical cannabis could feasibly be used as a replacement.

“We take our mission to provide safe, reliable medical cannabis formulations extremely seriously, and look forward to building upon our track record of success. Since medical cannabis became legal in Minnesota, 90 percent of patients have reported mild to significant benefits when surveyed by the Department of Health,” said Dr. Bachman. “Now that the state has extended access to patients with intractable pain, we hope we can save people not just from pain, but from the risks that can come with opioid use, such as accidental dependency, a mounting tolerance, and in some cases, even death.”

In order to schedule an appointment at a Care Center, patients with a qualifying medical condition who have received certification from their health care practitioners must first register with the Minnesota Department of Health’s Office of Medical Cannabis. After registering, they can consult with pharmacists and certified pharmacy technicians at LeafLine Labs to determine which specific botanically-formulated medications and recommended dosages are best for them and purchase their medical cannabis.

LeafLine Labs is one of two Minnesota organizations licensed to cultivate, process and distribute medical cannabis as part of the state’s medical cannabis program, which launched in the summer of 2015. Physician-founded and patient-care driven, LeafLine Labs delivers safe, reliable, sustainable and accessible formulations of botanically derived medication from the whole cannabis plant. We’re dedicated to providing knowledgeable, compassionate, authentic and dignified care to Minnesotans in need.

13 Challenges Filed Over Medical Marijuana Licenses

FLORIDA: Florida’s Department of Health has received 13 administrative challenges over the selection of nurseries to grow medical marijuana in the state.

An administrative challenge has been filed in all five regions. Redland Nursery filed challenges over the awarding of licenses in two regions.

The Office of Compassionate Care named the five nurseries Nov. 23. In order to qualify, nurseries had to have been in business in Florida for at least 30 years and grown a minimum of 400,000 plants at the time of the application.